Your browser doesn't support javascript.
loading
Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels, G J J; Scheper, W; Meringa, A D; Johanna, I; Beringer, D X; Janssen, A; Schiffler, M; Aarts-Riemens, T; Kramer, L; Straetemans, T; Heijhuurs, S; Leusen, J H W; San José, E; Fuchs, K; Griffioen, M; Falkenburg, J H; Bongiovanni, L; de Bruin, A; Vargas-Diaz, D; Altelaar, M; Heck, A J R; Shultz, L D; Ishikawa, F; Nishimura, M I; Sebestyén, Z; Kuball, J.
Afiliação
  • Kierkels GJJ; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Scheper W; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Meringa AD; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Johanna I; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Beringer DX; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Janssen A; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Schiffler M; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Aarts-Riemens T; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Kramer L; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Straetemans T; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Heijhuurs S; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Leusen JHW; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • San José E; Facultad de Ciencias Biomédicas y Salud, Universidad Europea, Madrid, Spain.
  • Fuchs K; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
  • Griffioen M; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
  • Falkenburg JH; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
  • Bongiovanni L; Department of Pathobiology, Faculty of Veterinary Medicine, Dutch Molecular Pathology Center, Utrecht University, Utrecht, The Netherlands.
  • de Bruin A; Department of Pathobiology, Faculty of Veterinary Medicine, Dutch Molecular Pathology Center, Utrecht University, Utrecht, The Netherlands.
  • Vargas-Diaz D; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, and.
  • Altelaar M; Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Heck AJR; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, and.
  • Shultz LD; Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Ishikawa F; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, and.
  • Nishimura MI; Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Sebestyén Z; Department of Immunology, The Jackson Laboratory, Bar Harbor, ME.
  • Kuball J; Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Blood Adv ; 3(19): 2870-2882, 2019 10 08.
Article em En | MEDLINE | ID: mdl-31585951
ABSTRACT
γδT cells are key players in cancer immune surveillance because of their ability to recognize malignant transformed cells, which makes them promising therapeutic tools in the treatment of cancer. However, the biological mechanisms of how γδT-cell receptors (TCRs) interact with their ligands are poorly understood. Within this context, we describe the novel allo-HLA-restricted and CD8α-dependent Vγ5Vδ1TCR. In contrast to the previous assumption of the general allo-HLA reactivity of a minor fraction of γδTCRs, we show that classic anti-HLA-directed, γδTCR-mediated reactivity can selectively act on hematological and solid tumor cells, while not harming healthy tissues in vitro and in vivo. We identified the molecular interface with proximity to the peptide-binding groove of HLA-A*2402 as the essential determinant for recognition and describe the critical role of CD8 as a coreceptor. We conclude that alloreactive γδT-cell repertoires provide therapeutic opportunities, either within the context of haplotransplantation or as individual γδTCRs for genetic engineering of tumor-reactive T cells.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T CD8-Positivos Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T CD8-Positivos Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2019 Tipo de documento: Article